RNAC
Cartesian Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.27
+1.64%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.2x
Market Cap
$280.47M
MomentumView details →
1D Return
+1.64%
YTD Return
+26.77%
RSI (14)
48.4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.2x
Market Cap
$280.47M
RSI (14)
48.4
MomentumView details →
1D Return
+1.64%
YTD Return
+26.77%
SummaryUpdated Jun 1, 2026
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) is a clinical-stage biopharmaceutical company that was incorporated in 2007 and is headquartered in Watertown, Massachusetts. The company operates under the business name Selecta Biosciences and focuses on developing innovative nanoparticle-based immunomodulatory drugs for treating and preventing human diseases. Originally founded as a biotechnology research company, Cartesian has evolved into a clinical-stage enterprise with multiple therapeutic programs spanning gene therapy, biologics, and autoimmune treatments, with several candidates advancing through various phases of clinical trials.
Similar companies
Latest newsMore news →
Cartesian Therapeutics reported Q2 2026 results with net income of $15.8 million and diluted EPS of $0.46, and cash and cash equivalents of $149.3 million at quarter end.30d agoCartesian Therapeutics entered into a credit facility with total potential non-dilutive funding of up to $150 million, with a first funded tranche of $50 million.30d ago